xRead - September 2022

Wise et al.

Page 360

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.1.a-1.

Evidence for the role of oral H 1 antihistamines in the management of allergic rhinitis Study Year LOE Study design Study groups Clinical endpoint Conclusion Mullol et al. 1175 2015 1a SR Rupatadine Allergy symptoms, ARIA criteria, AE Rupatadine is recommended for use in adults and children for intermittent/persistent AR and SAR/PAR. Ridolo et al. 1174 2015 1a SR Bilastine; cetirizine; desloratadine Subjective and objective measures, TNSS, RQLQ Scadding 1176 2015 1a Review of consensus statements: ARIA, EAACI, Royal College of

Bilastine at therapeutic dose has similar efficacy to other second-generation oral antihistamines. Demonstrated improvement in TNSS and RQLQ with good safety profile.

Paediatrics, and Child Health Oral antihistamines – Second-generation, non-sedating, antihistamines are recommended for mild to moderate AR and in combination for severe AR. Sedating antihistamines should not be used. analysis

Compalati & Canonica 1171 2013 1a SR Rupatadine Allergy symptoms, AE Favorable risk-benefit ratio for rupatadine in treating AR. Mösges et al. 1177 2013 1a SR and meta analysis Desloratadine; ebastine; fexofenadine; levocetirizine Compalati et al. 1178 2011 1a SR and meta Fexofenadine TSS, individual symptoms (sneezing, rhinorrhea, itching congestion), AE Ferrer 1179 2011 1a SR Levocetirizine; desloratadine; fexofenadine analysis Levocetirizine; loratadine

TSS and TNSS Second-generation levocetirizine significantly improved symptom scores especially in severe AR cases. TSS, PNIF, decongestion test, QOL, pruritus, ESS, wheal and flare, AE

Fexofenadine has good efficacy with improvement in outcome measures. No significant AE compared to placebo.

Oral newer-generation antihistamines are well tolerated in adults and children. Efficacy and improvement in QOL and nasal obstruction. Benefits outweigh harm. Very low risk of sedation. No QT prolongation found.

Improvement in TSS, Total 5 Symptoms Score, daytime nasal symptoms, and QOL.

Strong recommendation to use second-generation oral antihistamines that do not cause sedation and do not interact with CYP450 enzyme.

Oral antihistamines have good efficacy for improving both subjective and objective measures, effective in relieving nasal congestion associated with AR compared to placebo.

Rupatadine is a non-sedating, efficacious, and safe oral H1 antihistamine for intermittent/persistent, SAR/PAR.

TSS, DNS, DES, in patients with persistent and SAR/PAR Oral antihistamines Evidence was graded and recommendation given

TSS, PNIF, TSSC (with nasal obstruction), nasal congestion, and obstruction

ARIA criteria evaluated for: intermittent/persistent, SAR/PAR. TSS, DTSSm, DSSm, QT changes

Brozek et al. 1167 2010 1a SR with consensus Bachert 1182 2009 1a SR Desloratadine; fexofenadine; levocetirizine; statement

cetirizine; loratadine; terfenadine

Katiyar & Prakash 1181 2009 1a SR Rupatadine; ebastine;

cetirizine; loratadine; desloratadine

Mösges et al. 1180 2011 1a SR and meta

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.